Skip to main content
SpringerLink
Log in

Landiolol: A Review of its use in Intraoperative and Postoperative Tachyarrhythmias

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 02 July 2013

Abstract

Landiolol (Onoact®) is an intravenously administered, ultra short-acting β1-blocker with an elimination half-life of 3–4 min and ≈8-fold greater cardioselectivity than esmolol in vitro. It is approved in Japan for the treatment of intraoperative and postoperative tachyarrhythmias, but in clinical practice is also used to prevent postoperative tachyarrhythmias, such as atrial fibrillation after coronary artery bypass grafting. Randomized controlled trials in patients undergoing open-heart surgery demonstrated that various dosages of landiolol (0.0005–0.04 mg/kg/min) [0.5–40 μg/kg/min] were more effective than diltiazem in converting postoperative atrial fibrillation to normal sinus rhythm during the first 8 h after surgery, and were more effective than placebo (or no landiolol) in preventing the development of atrial fibrillation during the first week after surgery (primary efficacy endpoints). In patients undergoing surgical procedures, landiolol 0.125 mg/kg/min for 1 min followed by 0.04 mg/kg/min for 10 min was superior to placebo in improving intraoperative tachycardia in randomized double-blind trials. The beneficial effects of landiolol in attenuating adverse haemodynamic or other changes that can occur during surgery or invasive procedures (e.g. percutaneous coronary intervention) have been demonstrated in a large number of randomized controlled trials. For example, several studies showed that landiolol attenuated the increase in heart rate associated with tracheal intubation, without adversely affecting blood pressure or other haemodynamic parameters. Landiolol was generally well tolerated in clinical trials, with a relatively low risk of hypotension and bradycardia, although routine monitoring of cardiac function during landiolol administration is important. In general, adverse events such as reduced blood pressure resolve quickly after discontinuation of landiolol. Thus, as an ultra short-acting β1-blocker with a rapid onset of action and readily titratable and rapidly reversible effects, landiolol represents an important agent for the management of intraoperative and postoperative tachyarrhythmias.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cardinale D, Martinoni A, Cipolla CM, et al. Atrial fibrillation after operation for lung cancer: clinical and prognostic significance. Ann Thorac Surg. 1999;68(5):1827–31.

    Article  CAS  PubMed  Google Scholar 

  2. Roselli EE, Murthy SC, Rice TW, et al. Atrial fibrillation complicating lung cancer resection. J Thorac Cardiovasc Surg. 2005;130(2):438–44.

    Article  PubMed  Google Scholar 

  3. Creswell LL, Schuessler RB, Rosenbloom M, et al. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56(3):539–49.

    Article  CAS  PubMed  Google Scholar 

  4. Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996;94(3):390–7.

    Article  CAS  PubMed  Google Scholar 

  5. Melduni RM, Koshino Y, Shen WK. Management of arrhythmias in the perioperative setting. Clin Geriatr Med. 2012;28(4):729–43.

    Article  PubMed  Google Scholar 

  6. Almassi GH, Schowalter T, Nicolosi AC, et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg. 1997;226(4):501–11 (discussion 11–3).

    Google Scholar 

  7. Vaporciyan AA, Correa AM, Rice DC, et al. Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg. 2004;127(3):779–86.

    Article  PubMed  Google Scholar 

  8. Onoact (Onoakuto for injection, landiolol hydrochloride): Japanese prescribing information (revised April 2012); 2012. http://database.japic.or.jp/pdf/newPINS/00049024.pdf (Accessed 29 Apr 2013).

  9. Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull. 1992;40(6):1462–9.

    Article  CAS  PubMed  Google Scholar 

  10. Yamakage M, Iwasaki S, Jeong S-W, et al. Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009;38(1):48–55.

    Article  PubMed  Google Scholar 

  11. Motomura S, Hagihara A, Narumi Y, et al. Time course of a new ultrashort-acting beta-adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations. J Cardiovasc Pharmacol. 1998;31(3):431–40.

    Article  CAS  PubMed  Google Scholar 

  12. Sugiyama A, Takahara A, Hashimoto K. Electrophysiologic, cardiohemodynamic and beta-blocking actions of a new ultra-short-acting beta-blocker, ONO-1101, assessed by the in vivo canine model in comparison with esmolol. J Cardiovasc Pharmacol. 1999;34(1):70–7.

    Article  CAS  PubMed  Google Scholar 

  13. Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β-blocking agent in healthy volunteers (in Japanese). Rinsho Iyaku. 1997;13:4823–50.

    Google Scholar 

  14. Mizuno J, Yoshiya I, Yokoyama T, et al. Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia. Eur J Clin Pharmacol. 2007;63(3):243–52.

    Article  CAS  PubMed  Google Scholar 

  15. Ikeshita K, Nishikawa K, Toriyama S, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22(4):361–6.

    Article  PubMed  Google Scholar 

  16. Shibata S, Okamoto Y, Endo S, et al. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci. 2012;118(2):255–65.

    Article  CAS  PubMed  Google Scholar 

  17. Frishman WH, Saunders E. β-adrenergic blockers. J Clin Hypertens. 2011;13(9):649–53.

    Article  CAS  Google Scholar 

  18. Kimura-Kurosawa S, Kanaya N, Kamada N, et al. Cardioprotective effect and mechanism of action of landiolol on the ischemic reperfused heart. J Anesth. 2007;21(4):480–9.

    Article  PubMed  Google Scholar 

  19. Kurosawa S, Kanaya N, Niiyama Y, et al. Landiolol, esmolol and propranolol protect from ischemia/reperfusion injury in isolated guinea pig hearts. Can J Anaesth. 2003;50(5):489–94.

    Article  PubMed  Google Scholar 

  20. Zhao H, Sugawara T, Miura S, et al. Intrathecal landiolol inhibits nociception and spinal c-Fos expression in the mouse formalin test. Can J Anaesth. 2007;54(3):201–7.

    Article  PubMed  Google Scholar 

  21. Kurita T, Takata K, Morita K, et al. Lipophilic β-adrenoceptor antagonist propranolol increases the hypnotic and anti-nociceptive effects of isoflurane in a swine model. Br J Anaesth. 2008;100(6):841–5.

    Article  CAS  PubMed  Google Scholar 

  22. Tsunekawa K, Imawaka H, Yamamoto K, et al. Studies on the metabolic fate of ultra short acting β1-blocker ONO-1101 (3): metabolism and protein binding (in Japanese). Xenobio Metab Dispos. 1997;12:31–41.

    CAS  Google Scholar 

  23. Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β1-blocking agent in healthy volunteers (in Japanese). J Clin Ther Med. 2000;16(10):1531–56.

    Google Scholar 

  24. Honda N, Nakade S, Kasai H, et al. Population pharmacokinetics of landiolol hydrochloride in healthy subjects. Drug Metab Pharmacokinet. 2008;23(6):447–55.

    Article  CAS  PubMed  Google Scholar 

  25. Murakami M, Furuie H, Matsuguma K, et al. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting β1-selective blocker, in a dose escalation regimen in healthy male volunteers. Drug Metab Pharmacokinet. 2005;20(5):337–44.

    Article  CAS  PubMed  Google Scholar 

  26. Matsumoto N, Aomori T, Kanamoto M, et al. Influence of hemodynamic variations on the pharmacokinetics of landiolol in patients undergoing cardiovascular surgery. Biol Pharm Bull. 2012;35(10):1655–60.

    Article  CAS  PubMed  Google Scholar 

  27. Atarashi H, Kuruma A, Yashima M, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting β-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68(2):143–50.

    Article  CAS  PubMed  Google Scholar 

  28. Takahata T, Yasui-Furukori N, Sakamoto J, et al. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting β1-blocker. Drugs R D. 2005;6(6):385–94.

    Article  CAS  PubMed  Google Scholar 

  29. Inoue S, Abe R, Kawaguchi M, et al. Metoclopramide does not prolong duration of action of landiolol attenuating the hemodynamic response to induction of anesthesia and tracheal intubation. J Anesth. 2010;24(4):649–52.

    Article  PubMed  Google Scholar 

  30. Suzuki T, Aono M, Isaka T, et al. Effect of landiolol hydrochloride on suxamethonium-induced neuromuscular block. J Anesth. 2009;23(2):188–91.

    Article  PubMed  Google Scholar 

  31. Sezai A, Minami K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011;141(6):1478–87.

    Article  CAS  PubMed  Google Scholar 

  32. Sezai A, Nakai T, Hata M, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012;144(5):1241–8.

    Article  CAS  PubMed  Google Scholar 

  33. Sakamoto A, Kitakaze M, Takamoto S, et al. Landiolol, an ultra-short-acting β1-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J. 2012;76(5):1097–101.

    Article  CAS  PubMed  Google Scholar 

  34. Fujii M, Bessho R, Ochi M, et al. Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. J Cardiovasc Surg (Torino). 2012;53(3):369–74.

    CAS  Google Scholar 

  35. Osada H, Nakajima H, Masuyama S, et al. Landiolol hydrochloride: prevention of atrial fibrillation after open-heart surgery (abstract no. P606). Eur Heart J. 2012;33:65.

    Google Scholar 

  36. Nagaoka E, Arai H, Tamura K, et al. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2013; doi:10.5761/atcs.oa.12.02003.

    PubMed  Google Scholar 

  37. Sakaguchi M, Sasaki Y, Hirai H, et al. Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. Int Heart J. 2012;53(6):359–63.

    CAS  PubMed  Google Scholar 

  38. Ito N, Tashiro T, Morishige N, et al. Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction. Heart Surg Forum. 2012;15(4):E189–94.

    Article  PubMed  Google Scholar 

  39. Tanaka K. Effects of landiolol on hemodynamic improvement and prevention of atrial fibrillation in the perioperative period of off-pump coronary artery bypass grafting (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2010;63(3):175–9 (discussion 9–83).

  40. Fujiwara H, Sakurai M, Namai A, et al. Effect of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation after CABG surgery. Gen Thorac Cardiovasc Surg. 2009;57(3):132–7.

    Article  PubMed  Google Scholar 

  41. Yoshida Y, Terajima K, Sato C, et al. Clinical role and efficacy of landiolol in the intensive care unit. J Anesth. 2008;22(1):64–9.

    Article  PubMed  Google Scholar 

  42. To K, Iseki S, Setoguchi H. Landiolol hydrochloride improves the surgical Apgar score and outcome in off-pump coronary artery bypass surgery (abstract no. 700.00). Br J Anaesth. 2012;108:ii238.

    Google Scholar 

  43. Wakamatsu H, Yokoyama H. Intraoperative infusion of landiolol hydrochloride, an ultra-short acting beta-1 adrenergic receptor blocker, prevents postoperative atrial fibrillation after off-pump coronary artery bypass surgery (abstract). Chest. 2011;140(4 Meeting Abstracts):508A.

  44. Uehara K, Ueyama K, Ito H, et al. Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone? (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2010;63(3):188–91.

    Google Scholar 

  45. Ito S, Konishi T, Imazuru T, et al. Comparative study between landiolol and amiodarone for therapeutic efficacy after open heart surgery (in Japanese). Kyobu Geka (Jpn J Thorac Surg). 2011;64(13):1141–4.

    Google Scholar 

  46. Nakanishi K, Takeda S, Kim C, et al. Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol. J Cardiothorac Surg. 2013;8:19.

    Article  PubMed  Google Scholar 

  47. Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a phase III, double-blind study in comparison with placebo (in Japanese). Rinsyoiyaku (J Clin Ther Med). 1997;13:4949–78.

    Google Scholar 

  48. Yoshiya I, Ogawa R, Yasuhiro S. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia in patients with hypertension or cardiac ischemia: double-blind study in comparison with placebo (in Japanese). Rinsyoiyaku (J Clin Ther Med). 2002;18(9):1049–76.

    Google Scholar 

  49. Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of an ultra short acting beta-1-blocker landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a double-blind, dose finding study (late phase II study) (in Japanese). Rinsyoiyaku (J Clin Ther Med). 2000;16(10):1557–77.

    Google Scholar 

  50. Tanaka N, Watanabe T, Mishima T, et al. Prevention of atrial fibrillation recurrence with low-dose landiolol administration after radiofrequency catheter ablation (abstract). J Cardiovasc Electrophysiol. 2011;22:S109.

    Google Scholar 

  51. Nojiri T, Yamamoto K, Maeda H, et al. Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer. Gen Thorac Cardiovasc Surg. 2011;59(12):799–805.

    Article  PubMed  Google Scholar 

  52. Wariishi S, Yamashita K, Nishimori H, et al. Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose. Interact Cardiovasc Thorac Surg. 2009;9(5):811–3.

    Article  PubMed  Google Scholar 

  53. Nakano T, Shimizu K, Kawashima O, et al. Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. J Clin Pharm Ther. 2012;37(4):431–5.

    Article  CAS  PubMed  Google Scholar 

  54. Uratsuji Y, Ijichi K, Irie J, et al. Effect of landiolol hydrochloride (ONO-1101) infusion on perioperative supraventricular tachyarrhythmia in several times (in Japanese). Rinsyoiyaku (J Clin Ther Med). 1997;13:5009–26.

    Google Scholar 

  55. Ishigaki D, Arimoto T, Iwayama T, et al. Landiolol, an ultrashort-acting β-blocker, for prevention of atrial fibrillation after catheter ablation (abstract no. P2374). Eur Heart J. 2012;33:352.

    Google Scholar 

  56. Koyanagi K, Seishima R, Tabuchi S, et al. Usefulness of short-acting β1 selective blocker (landiolol hydrochloride) for postoperative tachyarrhythmia after radical operation of esophageal cancer (abstract). Dis Esophagus. 2010;23:114A–5A.

    Google Scholar 

  57. Okita T, Uji M, Shinjo T, et al. Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection (in Japanese). Jpn J Anesthesiol. 2008;57(8):953–8.

    Google Scholar 

  58. Sugimoto R, Nakayama Y, Nawa Y. Administration of landiolol decreases the incidence of atrial fibrillation after lung lobectomy (abstract no. A1141). Annual Meeting of the American Society of Anesthesiologists, San Diego;2010.

  59. Taenaka N, Amaha K. Dose-dependent effect of landiolol, a new ultra-short-acting β1-blocker, on supraventricular tachyarrhythmias in postoperative patients. Clin Drug Investig. 2013; doi:10.1007/s40261-013-0093x.

  60. Kawaguchi M, Utada K, Yoshitani K, et al. Effects of a short-acting β1-receptor antagonist landiolol on hemodynamics and tissue injury markers in patients with subarachnoid hemorrhage undergoing intracranial aneurysm surgery. J Neurosurg Anesthesiol. 2010;22(3):230–9.

    Article  PubMed  Google Scholar 

  61. Harasawa R, Hayashi Y, Iwasaki M, et al. Bolus administration of landiolol, a short-acting, selective β1-blocker, to treat tachycardia during anesthesia: a dose-dependent study. J Cardiothorac Vasc Anesth. 2006;20(6):793–5.

    Article  CAS  PubMed  Google Scholar 

  62. Fox EJ, Sklar GS, Hill CH, et al. Complications related to the pressor response to endotracheal intubation. Anesthesiology. 1977;47(6):524–5.

    Article  CAS  PubMed  Google Scholar 

  63. Forbes AM, Dally FG. Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man. Br J Anaesth. 1970;42(7):618–24.

    Article  CAS  PubMed  Google Scholar 

  64. Tanabe T, Fukusaki M, Fujinaga A, et al. Landiolol, a new ultra-short-acting β1-blocker, reduces anaesthetic requirement during sevoflurane/N2O/fentanyl anaesthesia in surgical patients. Eur J Anaesthesiol. 2009;26(1):39–42.

    Article  CAS  PubMed  Google Scholar 

  65. Kitamura A, Sakamoto A, Inoue T, et al. Efficacy of an ultrashort-acting β-adrenoceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation. Eur J Clin Pharmacol. 1997;51(6):467–71.

    Article  CAS  PubMed  Google Scholar 

  66. Yamazaki A, Kinoshita H, Shimogai M, et al. Landiolol attenuates tachycardia in response to endotracheal intubation without affecting blood pressure. Can J Anaesth. 2005;52(3):254–7.

    Article  PubMed  Google Scholar 

  67. Ishikawa K, Shirakawa K, Nagao M, et al. Comparison of remifentanil and landiolol on hemodynamic and plasma catecholamine responses to tracheal intubation. Dokkyo J Med Sci. 2012;39(1):1–8.

    CAS  Google Scholar 

  68. Kadoi Y, Horiuchi T, Uchida S, et al. Adequacy of control of preoperative hypertension can affect landiolol-induced hemodynamic changes in elderly patients during emergence from anesthesia. J Anesth. 2011;25(2):271–7.

    Article  PubMed  Google Scholar 

  69. Kawaguchi M, Kawaraguchi Y, Yamamoto Y, et al. Effects of landiolol on systemic and cerebral hemodynamics and recovery from anesthesia in patients undergoing craniotomy. J Anesth. 2010;24(4):503–10.

    Article  PubMed  Google Scholar 

  70. Miyazaki M, Kadoi Y, Saito S. Effects of landiolol, a short-acting β1-blocker, on hemodynamic variables during emergence from anesthesia and tracheal extubation in elderly patients with and without hypertension. J Anesth. 2009;23(4):483–8.

    Article  PubMed  Google Scholar 

  71. Shirasaka T, Iwasaki T, Hosokawa N, et al. Effects of landiolol on the cardiovascular response during tracheal extubation. J Anesth. 2008;22(3):322–5.

    Article  PubMed  Google Scholar 

  72. Suehiro K, Okutani R. Landiolol attenuates cardiovascular response at induction of general anesthesia for cesarean delivery. J Anesth. 2012;26(2):200–5.

    Article  PubMed  Google Scholar 

  73. Oda Y, Nishikawa K, Hase I, et al. The short-acting β1-adrenoceptor antagonists esmolol and landiolol suppress the bispectral index response to tracheal intubation during sevoflurane anesthesia. Anesth Analg. 2005;100(3):733–7.

    Article  CAS  PubMed  Google Scholar 

  74. Sugiura S, Seki S, Hidaka K, et al. The hemodynamic effects of landiolol, an ultra-short-acting β1-selective blocker, on endotracheal intubation in patients with and without hypertension. Anesth Analg. 2007;104(1):124–9.

    Article  CAS  PubMed  Google Scholar 

  75. Kawaguchi M, Takamatsu I, Masui K, et al. Effect of landiolol on bispectral index and spectral entropy responses to tracheal intubation during propofol anaesthesia. Br J Anaesth. 2008;101(2):273–8.

    Article  CAS  PubMed  Google Scholar 

  76. Goyagi T, Tanaka M, Nishikawa T. Landiolol attenuates the cardiovascular response to tracheal intubation. J Anesth. 2005;19(4):282–6.

    Article  PubMed  Google Scholar 

  77. Hirata N, Miyashita R, Watanabe A, et al. Low-dose continuous infusion of landiolol can reduce adrenergic response during tracheal intubation in elderly patients with cardiovascular disease. J Anesth. 2010;24(5):786–8.

    Article  PubMed  Google Scholar 

  78. Hirota K, Baba S, Fukushi S, et al. Efficacy of landiolol in attenuating hemodynamic responses to local epinephrine infiltration in patients undergoing vaginal total hysterectomy. J Anesth. 2005;19(1):17–20.

    Article  PubMed  Google Scholar 

  79. Horiuchi T, Uchida S, Kadoi Y, et al. Landiolol infusion attenuates increase in heart rate, but does not prevent increase in blood pressure in response to emergence from anesthesia and tracheal extubation (in Japanese). Jpn J Anesthesiol. 2010;59(9):1178–84.

    Google Scholar 

  80. Onaka M, Yamamoto H. Effects of continuous infusion of landiolol on the hemodynamic response to tracheal intubation (in Japanese). Jpn J Anesthesiol. 2006;55(2):174–8.

    Google Scholar 

  81. Kawano T, Eguchi S, Iseki A, et al. Effects of landiolol on cardiovascular responses, bispectral index and body movement during endotracheal intubation (in Japanese). Jpn J Anesthesiol. 2005;54(6):610–4.

    Google Scholar 

  82. Tachikawa M, Shimazaki M, Arai T, et al. Effect of landiolol and combined use of landiolol and olprinone on hemodynamics in patients undergoing off-pump coronary artery bypass grafting [in Japanese]. Jpn J Anesthesiol. 2012;61(6):566–73.

    Google Scholar 

  83. Nishiyama Y. The effect of landiolol on bispectral index scores in patients undergoing lower abdominal surgery (in Japanese). Jpn J Anesthesiol. 2012;61(2):217–20.

    Google Scholar 

  84. Goto K, Shingu C, Miyamoto S, et al. The effect of landiolol on hemodynamics and left ventricular function in patients with coronary artery disease. J Clin Anesth. 2007;19(7):523–9.

    Article  CAS  PubMed  Google Scholar 

  85. Miyazaki M, Kadoi Y, Takashi S, et al. Comparative effects of propofol, landiolol, and nicardipine on hemodynamic and bispectral index responses to endotracheal intubation: a prospective, randomized, double-blinded study. J Clin Anesth. 2008;20(4):257–62.

    Article  CAS  PubMed  Google Scholar 

  86. Kaneko M, Yamaguchi S, Hamaguchi S, et al. Effects of landiolol on QT interval and QT dispersion during induction of anesthesia using computerized measurement. J Clin Anesth. 2009;21(8):555–61.

    Article  CAS  PubMed  Google Scholar 

  87. Inoue S, Tanaka Y, Kawaguchi M, et al. The efficacy of landiolol for suppressing the hyperdynamic response following laryngoscopy and tracheal intubation: a systematic review. Anaesth Intensive Care. 2009;37(6):893–902.

    CAS  PubMed  Google Scholar 

  88. Nonaka A, Suzuki S, Abe F. The effects of continuous infusion of landiolol on heart rate changes after neostigmine-atropine administration during recovery from general anesthesia (in Japanese). Jpn J Anesthesiol. 2006;55(12):1459–62.

    Google Scholar 

  89. Wajima Z, Tsuchida H, Shiga T, et al. Intravenous landiolol, a novel β1-adrenergic blocker, reduces the minimum alveolar concentration of sevoflurane in women. J Clin Anesth. 2011;23(4):292–6.

    Article  CAS  PubMed  Google Scholar 

  90. Takizawa D, Saito S, Sato E, et al. Influence of landiolol on the dose requirement of propofol for induction of anesthesia. Fundam Clin Pharmacol. 2005;19(5):597–9.

    Article  CAS  PubMed  Google Scholar 

  91. Goto K, Hagiwara S, Hidaka S, et al. The effect of landiolol on cerebral blood flow in patients undergoing off-pump coronary artery bypass surgery. J Anesth. 2010;24(1):11–6.

    Article  PubMed  Google Scholar 

  92. Matsura M, Fujiwara Y, Ito H, et al. Prolongation of QT interval induced by electroconvulsive therapy is attenuated by landiolol. J ECT. 2010;26(1):37–40.

    Article  CAS  PubMed  Google Scholar 

  93. Nomoto K, Suzuki T, Serada K, et al. Effects of landiolol on hemodynamic response and seizure duration during electroconvulsive therapy. J Anesth. 2006;20(3):183–7.

    Article  PubMed  Google Scholar 

  94. Sakamoto A, Ogawa R, Suzuki H, et al. Landiolol attenuates acute hemodynamic responses but does not reduce seizure duration during maintenance electroconvulsive therapy. Psychiatry Clin Neurosci. 2004;58(6):630–5.

    Article  CAS  PubMed  Google Scholar 

  95. Saito S, Nishihara F, Akihiro T, et al. Landiolol and esmolol prevent tachycardia without altering cerebral blood flow. Can J Anaesth. 2005;52(10):1027–34.

    Article  PubMed  Google Scholar 

  96. Ide M, Kadoi Y, Saito S, et al. Effects of landiolol on left ventricular function during electroconvulsive therapy: a transthoracic echocardiographic study. J Anesth. 2010;24(2):272–6.

    Article  PubMed  Google Scholar 

  97. Wajima Z, Shiga T, Imanaga K, et al. Prophylactic continuous administration of landiolol, a novel β1 blocker, blunts hyperdynamic responses during electroconvulsive therapy without altering seizure activity. Int J Psych Clin Pract. 2010;14(2):132–6.

    Article  CAS  Google Scholar 

  98. Park H, Otani H, Noda T, et al. Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention. Int J Cardiol. 2012; doi:10.1016/j.ijcard.2012.04.096.

    Google Scholar 

  99. Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76(2):439–45.

    Article  CAS  PubMed  Google Scholar 

  100. Hoshi T, Sato A, Nishina H, et al. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study. J Cardiol. 2012;60(4):252–6.

    Article  PubMed  Google Scholar 

  101. Higuchi H. Feasibility of continuous intravenous administration of landiolol for acute myocardial infarction: first clinical experience and its safe directions for use (abstract no. E953). J Am Coll Cardiol. 2010;55(10 Suppl):A102.

    Google Scholar 

  102. Morita H, Kono T, Suzuki S, et al. Intravenous administration of subdepressor dose of short-acting beta-blocker landiolol before percutaneous coronary intervention may reduce the incidence of myocardial infarction in stable angina (abstract no. 1041-157). J Am Coll Cardiol. 2009:A342.

  103. Mitchell LB. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol. 2011;27(1):91–7.

    Article  PubMed  Google Scholar 

  104. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009;30(22):2769–812.

    Article  PubMed  Google Scholar 

  105. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123(10):e269–367.

    Article  PubMed  Google Scholar 

  106. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias - executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42(8):1493–531.

    Article  PubMed  Google Scholar 

  107. Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs. 2012;72(1):109–32.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes based on any comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Greg L. Plosker

Authors
  1. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Greg L. Plosker.

Additional information

The manuscript was reviewed by: H. Arai, Department of Cardiovascular Surgery, Tokyo Medical and Dental University, Tokyo, Japan; T. Hoshi, Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; M. Kawaguchi, Department of Anesthesiology, Nara Medical University, Nara, Japan; Y. Oda, Department of Anesthesiology and Intensive Care Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan; K. Okumura, Department of Cardiology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; H. Otani, Second Department of Internal Medicine, Kansai Medical University, Moriguchi City, Japan; K. Suehiro, Department of Anesthesiology, Osaka City General Hospital and Children Hospital, Osaka, Japan; Z. Wajima, Department of Anesthesiology, Hioya Hospital, International University of Health and Welfare, Yaita-shi, Japan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plosker, G.L. Landiolol: A Review of its use in Intraoperative and Postoperative Tachyarrhythmias. Drugs 73, 959–977 (2013). https://doi.org/10.1007/s40265-013-0077-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0077-4

Keywords

Search

Navigation